Clinical Trial Update: Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury? [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial investigates whether seven days of dipyridamole treatment can provide protection against ischemia-reperfusion injury; the study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Ischemia-reperfusion Injury

Drugs mentioned

• Dipyridamole (Dipyridamole)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Ischemia-Reperfusion Injury, Atherosclerosis | Phase 4 | Status: COMPLETED